Journal of Dementia

Johnson et al., J Dement 2024, 8:3

Research Article Open Access

The Spectrum of Dementia includes Alzheimer's Disease and other common types such as Vascular Dementia, Lewy Body Dementia, and Front temporal Dementia.

James Johnson[1]*, Elizabeth Brown[2], Michael Moore[3] and William Miller[1]

[1]*Department of Impairments and Neurological Disorders, University of California, Irvine, USA*
[2]*Department of Alzheimer Disease, University of Pittsburgh, USA*
[3]*Department of Dementia, University of Rochester, USA*

Abstract

Dementia presents a significant public health challenge, with Alzheimer's disease accounting for a substantial portion of cases. This paper explores the prevalence and impact of Alzheimer's disease, constituting 50% to 70% of dementia cases. It also delves into other common types such as vascular dementia (25%), Lewy body dementia (15%), and frontotemporal dementia. Additionally, the paper touches upon less common forms like post-traumatic dementia, Parkinson's disease-related dementia, alpha-synuclein-associated dementia, Huntington's disease, normal pressure hydrocephalus, Creutzfeldt–Jakob disease, and dementia in Down syndrome. Understanding the spectrum of dementia is crucial for effective management and care strategies.

Keywords: Alzheimer's disease; Vascular dementia; Lewy body dementia; Frontotemporal dementia; Parkinson's disease-related dementia; Alpha-synuclein-associated dementia; Huntington's disease; Normal pressure hydrocephalus; Creutzfeldt–Jakob disease

Introduction

Dementia is a progressive neurological condition characterized by a decline in cognitive function that interferes with daily life. It is a major public health concern globally, with significant implications for individuals, families, and healthcare systems. The most common type of dementia is Alzheimer's disease, accounting for approximately 50% to 70% of all cases. However, there are several other types of dementia, each with its unique clinical features and underlying causes. Vascular dementia, resulting from reduced blood flow to the brain, is the second most prevalent form of dementia, constituting around 25% of cases. Lewy body dementia, characterized by the presence of abnormal protein deposits in the brain, accounts for approximately 15% of dementia cases and presents with a distinct set of symptoms, including visual hallucinations and fluctuating cognition [1]. Frontotemporal dementia, affecting the frontal and temporal lobes of the brain, is another significant subtype, albeit less common than Alzheimer's disease and vascular dementia.

In addition to these well-known types, there are other forms of dementia that merit attention. Post-traumatic dementia, arising from head injuries or trauma, poses unique challenges in diagnosis and management. Dementia associated with Parkinson's disease, marked by motor impairments and cognitive decline, represents another important subset. Furthermore, alpha-synuclein-associated dementia, Huntington's disease-related dementia, normal pressure hydrocephalus, Creutzfeldt–Jakob disease, and dementia in individuals with Down syndrome contribute to the diverse spectrum of cognitive disorders [2]. Understanding the prevalence, clinical manifestations, and underlying pathology of these various types of dementia is essential for accurate diagnosis, effective management, and targeted interventions. Moreover, advancing our knowledge of the interplay between genetic, environmental, and lifestyle factors in dementia development can inform preventive strategies and personalized treatment approaches. This research article aims to explore the landscape of dementia, focusing on Alzheimer's disease and its prevalence, as well as delving into other common and less common types of dementia. By synthesizing existing literature and presenting current perspectives, this study seeks to contribute to the broader understanding of dementia and guide future research directions and clinical practices [3].

The global burden of dementia

Dementia represents a significant global health burden, affecting millions of individuals worldwide. The prevalence and incidence of dementia have been steadily rising, primarily due to population aging and increased awareness and diagnostic capabilities. According to recent estimates, there are over 50 million people living with dementia globally, with this number expected to double every 20 years. The prevalence of dementia varies across different regions and age groups, with higher rates observed in older populations. Studies suggest that approximately 5-7% of individuals aged 60 and above have dementia, with the prevalence increasing exponentially with age. The incidence of new cases of dementia is also substantial, highlighting the urgent need for effective prevention and management strategies (Table 1).

Impact on individuals and society

Dementia exerts a profound impact on individuals, families, and society as a whole. It leads to progressive cognitive decline, memory loss, and difficulties in performing daily activities, ultimately affecting quality of life. Moreover, dementia imposes significant emotional, financial, and social burdens on caregivers and healthcare systems, emphasizing the need for comprehensive support and services.

***Corresponding author:** James Johnson, Department of Impairments and Neurological Disorders, University of California, Irvine, USA, Email: James.John@son.edu

Received: 2-May-2024, Manuscript No: dementia-24-138215, **Editor assigned:** 05-May-2024, PreQC No: dementia-24-138215 (PQ), **Reviewed:** 19-May-2024, QC No: dementia-24-138215, **Revised:** 22- May-2024, Manuscript No: dementia-24-138215 (R), **Published:** 29-May-2024, DOI: 10.4172/dementia.1000218

Citation: Johnson J (2024) The Spectrum of Dementia includes Alzheimer's Disease and other common types such as Vascular Dementia, Lewy Body Dementia, and Front temporal Dementia. J Dement 8: 218.

Table 1: Prevalence of Dementia Subtypes.

Dementia Subtype	Prevalence Range (%)
Alzheimer's Disease	50% - 70%
Vascular Dementia	20% - 30%
Lewy Body Dementia	10% - 15%
Frontotemporal Dementia	5% - 10%
Post-Traumatic Dementia	2% - 5%
Parkinson's Disease-Related Dementia	2% - 5%
Alpha-Synuclein-Associated Dementia	1% - 3%
Huntington's Disease	<1%
Normal Pressure Hydrocephalus	<1%
Creutzfeldt–Jakob Disease	<1%
Dementia in Down Syndrome	<1%

The complex nature of dementia presents numerous challenges for healthcare systems worldwide. These challenges include early diagnosis and intervention, access to specialized care and resources, caregiver support, and addressing the stigma associated with dementia [4]. Furthermore, the long-term management of dementia requires a multidisciplinary approach involving healthcare professionals, social services, and community organizations. Alzheimer's disease is the most common form of dementia, accounting for the majority of cases. It is a progressive neurodegenerative disorder characterized by the accumulation of amyloid plaques and tau tangles in the brain, leading to neuronal damage and cognitive decline. The hallmark symptoms of Alzheimer's disease include memory loss, confusion, disorientation, and changes in behavior and personality.

Definition and characteristics

Alzheimer's disease is characterized by progressive cognitive decline, typically starting with episodic memory impairment and progressing to severe dementia stages. The cognitive deficits in Alzheimer's disease affect multiple domains, including memory, language, executive function, and visuospatial skills. As the disease advances, individuals may experience difficulties in communication, decision-making, and independent living [5].

Pathophysiology and biomarkers

The pathophysiology of Alzheimer's disease involves the abnormal accumulation of beta-amyloid plaques and tau protein tangles in the brain, leading to synaptic dysfunction, neuronal loss, and brain atrophy. Biomarkers such as amyloid-beta and tau proteins in cerebrospinal fluid or neuroimaging techniques like positron emission tomography (PET) scans can aid in the early diagnosis and monitoring of Alzheimer's disease progression.

Diagnostic criteria and screening tools

Diagnostic criteria for Alzheimer's disease include clinical assessments, cognitive testing, neuroimaging, and biomarker analysis. The most widely used diagnostic criteria are based on the National Institute on Aging and Alzheimer's Association (NIA-AA) guidelines, which incorporate clinical symptoms, biomarker evidence, and exclusion of other potential causes of cognitive impairment. Screening tools such as the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) are commonly used to assess cognitive function and screen for potential dementia in clinical settings (Table 2).

Other common types of dementia

In addition to Alzheimer's disease, several other common types of dementia exist, each with its distinct clinical features, underlying pathology, and management considerations. These include vascular dementia, Lewy body dementia, and frontotemporal dementia, among others [6].

Table 2: Diagnostic Criteria for Dementia Subtypes.

Dementia Subtype	Diagnostic Criteria
Alzheimer's Disease	NIA-AA criteria, based on clinical symptoms and biomarkers
Vascular Dementia	Hachinski Ischemic Score, neuroimaging findings
Lewy Body Dementia	Consensus criteria (McKeith criteria), clinical features
Frontotemporal Dementia	International Consensus Criteria (Rascovsky criteria)
Post-Traumatic Dementia	History of head injury, cognitive assessments
Parkinson's Disease-Related Dementia	Clinical symptoms, neuroimaging, progression
Alpha-Synuclein-Associated Dementia	Clinical symptoms, biomarker evidence
Huntington's Disease	Genetic testing (HTT gene mutation), clinical symptoms
Normal Pressure Hydrocephalus	Clinical symptoms, neuroimaging findings
Creutzfeldt–Jakob Disease	EEG findings, CSF analysis, clinical symptoms
Dementia in Down Syndrome	Clinical assessment, cognitive testing, genetic factors

Vascular dementia

Vascular dementia is the second most prevalent form of dementia, accounting for around 25% of cases. It is caused by reduced blood flow to the brain due to cerebrovascular disease, such as strokes or small vessel disease. The clinical presentation of vascular dementia varies depending on the location and extent of vascular damage, leading to cognitive impairments, motor deficits, and mood changes. Subtypes of vascular dementia include multi-infarct dementia, strategic infarct dementia, and subcortical vascular dementia. The primary causes of vascular dementia are vascular lesions and ischemic events that disrupt cerebral blood flow and oxygen delivery to brain tissues. Risk factors for developing vascular dementia include hypertension, diabetes, smoking, hypercholesterolemia, atrial fibrillation, and a history of stroke or transient ischemic attacks (TIAs).

Clinical features and subtypes

The clinical features of vascular dementia encompass a spectrum of cognitive impairments, including memory deficits, executive dysfunction, attentional deficits, and visuospatial difficulties. The specific subtype of vascular dementia influences the pattern and severity of cognitive symptoms, as well as associated neurological deficits such as gait disturbances, urinary incontinence, and mood disturbances [7].

Lewy body dementia

Lewy body dementia (LBD) is characterized by the presence of abnormal protein deposits called Lewy bodies in the brain, which are composed of alpha-synuclein aggregates. LBD encompasses two main clinical subtypes: dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). Both subtypes share similar neuropathological features but differ in the timing and predominance of motor and cognitive symptoms.

Neuropathology and protein deposits

The neuropathology of Lewy body dementia involves widespread

distribution of Lewy bodies in the cerebral cortex, brainstem, and subcortical regions. These protein deposits disrupt neuronal function, neurotransmitter systems (particularly dopamine), and synaptic transmission, leading to motor dysfunction, cognitive impairment, and neuropsychiatric symptoms. Lewy body dementia presents with a complex array of symptoms, including cognitive fluctuations, visual hallucinations, parkinsonism (bradykinesia, rigidity, tremor), REM sleep behavior disorder (RBD), and autonomic dysfunction. The overlap of symptoms with other neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, poses diagnostic challenges and underscores the importance of comprehensive clinical assessments and biomarker evaluations [8].

Frontotemporal dementia

Frontotemporal dementia (FTD) is a heterogeneous group of neurodegenerative disorders characterized by progressive changes in behavior, personality, language, and executive function. It primarily affects the frontal and temporal lobes of the brain, leading to social disinhibition, apathy, language deficits (semantic variant primary progressive aphasia), and executive dysfunction (behavioral variant FTD).

Behavioral and language variants

FTD encompasses several clinical variants, including behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and non-fluent variant primary progressive aphasia (nfvPPA). Each variant presents with distinct clinical features and underlying neuropathological changes, such as frontotemporal lobar degeneration (FTLD) characterized by tau, TDP-43, or FUS proteinopathy.

Genetic factors and molecular mechanisms

Genetic mutations in genes such as MAPT (microtubule-associated protein tau), GRN (progranulin), and C9orf72 (chromosome 9 open reading frame 72) are implicated in familial forms of frontotemporal dementia. These genetic factors influence disease onset, progression, and clinical phenotypes, highlighting the complex interplay between genetic susceptibility and environmental factors in FTD pathogenesis. In addition to the well-known types of dementia discussed above, there are less common forms and special considerations that warrant attention in clinical practice and research [9].

Post-traumatic dementia

Post-traumatic dementia refers to cognitive impairments and neurological deficits resulting from head injuries or trauma, such as concussions, contusions, or penetrating brain injuries. Traumatic brain injury (TBI) can lead to a range of cognitive and behavioral changes, including memory problems, executive dysfunction, mood disturbances, and physical impairments.

Traumatic brain injury and cognitive impairment

The severity and long-term consequences of post-traumatic dementia depend on factors such as the extent of brain injury, age at injury, repetitive head trauma (as seen in sports-related injuries or military service), and pre-existing cognitive vulnerabilities. TBI-related cognitive impairment may manifest as deficits in attention, processing speed, working memory, and problem-solving abilities. Diagnosing post-traumatic dementia involves comprehensive neuropsychological assessments, neuroimaging studies (CT, MRI), and consideration of the individual's medical history and risk factors. Management strategies focus on optimizing cognitive function, addressing behavioral and emotional changes, and promoting neurorehabilitation and functional independence (Table 3).

Parkinson's disease-related dementia

Parkinson's disease-related dementia (PDD) is a common complication of Parkinson's disease (PD), a neurodegenerative disorder characterized by motor symptoms such as tremor, rigidity, bradykinesia, and postural instability. PDD refers to cognitive decline and dementia that occurs in the later stages of PD, affecting approximately 50-80% of individuals with PD over time. PDD is characterized by a combination of motor symptoms associated with PD and cognitive deficits such as memory impairment, executive dysfunction, and visuospatial difficulties. The overlapping neuropathological features of PD and PDD involve alpha-synuclein pathology, Lewy bodies, and neuroinflammation in multiple brain regions. Managing PDD involves a multidisciplinary approach, including pharmacological interventions (cholinesterase inhibitors, memantine) to improve cognitive function and motor symptoms, along with non-pharmacological strategies such as cognitive rehabilitation, physical therapy, and caregiver support. Ongoing research aims to unravel the underlying mechanisms of PDD, develop disease-modifying therapies, and enhance quality of life for individuals with Parkinson's disease [10].

Alpha-synuclein-associated dementia

Alpha-synuclein-associated dementia encompasses a spectrum of neurodegenerative disorders characterized by alpha-synuclein pathology and clinical features overlapping with Parkinson's disease and Lewy body dementia. These disorders include multiple system atrophy (MSA), pure autonomic failure (PAF), and dementia with Lewy bodies (DLB), collectively referred to as synucleinopathies.

Relationship to parkinson's disease and lewy body dementia

Synucleinopathies share common pathophysiological mechanisms involving alpha-synuclein aggregation, neuronal dysfunction, and

Table 3: Treatment Options for Dementia Subtypes.

Dementia Subtype	Treatment Options
Alzheimer's Disease	Cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, cognitive stimulation
Vascular Dementia	Management of vascular risk factors (hypertension, diabetes), cognitive rehabilitation
Lewy Body Dementia	Cholinesterase inhibitors, dopaminergic medications, management of visual hallucinations
Frontotemporal Dementia	Symptomatic management (behavioral interventions, speech therapy), clinical trials targeting specific FTD subtypes
Post-Traumatic Dementia	Cognitive rehabilitation, neurobehavioral interventions, symptom management
Parkinson's Disease-Related Dementia	Dopaminergic medications, cholinesterase inhibitors, physical therapy
Alpha-Synuclein-Associated Dementia	Symptomatic treatment, clinical trials targeting alpha-synuclein pathology
Huntington's Disease	Symptomatic management (movement disorders, psychiatric symptoms), genetic counseling
Normal Pressure Hydrocephalus	Ventriculoperitoneal shunting, cognitive rehabilitation, symptom management
Creutzfeldt–Jakob Disease	Supportive care, symptom management, palliative interventions
Dementia in Down Syndrome	Early intervention, behavioral therapies, caregiver support

neuroinflammation, leading to motor dysfunction, autonomic dysfunction, and cognitive decline. The distinction between synucleinopathies lies in the predominant clinical manifestations (motor vs. cognitive vs. autonomic), although overlap and mixed presentations are common. The neurobiological features of alpha-synuclein-associated dementia include alpha-synuclein aggregates in neurons and glial cells, neuronal loss, gliosis, and neurotransmitter dysregulation. The clinical heterogeneity of synucleinopathies underscores the need for personalized diagnostic and therapeutic approaches tailored to individual symptoms, disease progression, and underlying neuropathology.

Other Rare Forms (Huntington's disease, normal pressure hydrocephalus, Creutzfeldt–Jakob disease, dementia in Down syndrome)

Less common forms of dementia, such as Huntington's disease, normal pressure hydrocephalus (NPH), Creutzfeldt–Jakob disease (CJD), and dementia in Down syndrome, pose unique challenges in diagnosis, management, and care. These conditions have distinct etiologies, clinical features, and genetic or acquired factors contributing to cognitive impairment and neurodegeneration. Each rare form of dementia presents with unique features, such as chorea and psychiatric symptoms in Huntington's disease, gait disturbances and urinary incontinence in NPH, rapidly progressive dementia and prion protein accumulation in CJD, and early-onset cognitive decline in individuals with Down syndrome [11]. The diagnostic challenges in these conditions include genetic testing, neuroimaging, cerebrospinal fluid analysis, and clinical assessments to differentiate from other neurodegenerative or acquired causes of dementia.

Advances in genetic testing and therapeutic options

Advances in genetic testing, biomarker discovery, and neuroimaging techniques have improved the early detection and differential diagnosis of rare forms of dementia. Targeted therapies, disease-modifying interventions, and supportive care strategies are evolving to address the specific pathophysiological mechanisms and clinical needs of individuals with rare dementias. Comprehensive understanding of the diverse spectrum of dementia, including common and rare forms, is essential for accurate diagnosis, personalized treatment, and improved outcomes for affected individuals and their families. Challenges in differential diagnosis, access to specialized care, and ongoing research efforts underscore the importance of collaborative efforts among healthcare professionals, researchers, policymakers, and advocacy groups.

Importance of accurate diagnosis

Accurate diagnosis of dementia is critical for initiating appropriate interventions, planning for long-term care, and optimizing quality of life for affected individuals. Differential diagnosis involves thorough clinical assessments, cognitive testing, neuroimaging studies, and consideration of genetic and environmental factors that may contribute to cognitive impairment. Challenges in differential diagnosis of dementia include distinguishing between various subtypes based on clinical presentations, neuropathological features, biomarker profiles, and exclusion of reversible or comorbid conditions that may mimic dementia symptoms. The overlap of cognitive, behavioral, and motor symptoms across different dementia syndromes adds complexity to diagnostic evaluations.

Implications for patient care and management

Accurate diagnosis of dementia has significant implications for patient care and management, including personalized treatment plans, medication management, cognitive rehabilitation, caregiver support, and advance care planning. Early detection of dementia allows for timely interventions to delay disease progression, improve symptom management, and enhance overall quality of life for individuals living with dementia and their caregivers [12].

Research objectives and scope

The objectives of this research study encompass a comprehensive review and synthesis of current literature on dementia, including common and rare forms, diagnostic criteria, biomarkers, treatment approaches, and research trends. The scope of the study includes examining the latest advancements in understanding the pathophysiology of dementia, exploring novel diagnostic tools and therapeutic strategies, and identifying areas for future research and clinical practice. The primary aims of the current study are to provide a comprehensive overview of dementia subtypes, highlight diagnostic challenges and advancements, discuss treatment options and management strategies, and identify research priorities for advancing our understanding of dementia pathogenesis and improving patient outcomes. By synthesizing existing knowledge and identifying gaps in the literature, this study aims to contribute to the broader field of dementia research and clinical practice. The study involves a thorough literature review of peer-reviewed articles, clinical guidelines, meta-analyses, systematic reviews, and expert consensus statements on dementia epidemiology, etiology, diagnosis, and management. The synthesis of literature will focus on key themes, emerging trends, controversies, and consensus recommendations in the field of dementia research and clinical [13].

Methodology

This study employed a systematic review methodology to gather and analyze relevant literature on the various types of dementia, including Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, post-traumatic dementia, Parkinson's disease-related dementia, alpha-synuclein-associated dementia, Huntington's disease, normal pressure hydrocephalus, Creutzfeldt–Jakob disease, and dementia in Down syndrome. A comprehensive search strategy was devised to identify peer-reviewed articles, clinical guidelines, meta-analyses, systematic reviews, and expert consensus statements published in electronic databases such as PubMed, MEDLINE, Embase, PsycINFO, and Cochrane Library. The search terms included combinations of "dementia," "Alzheimer's disease," "vascular dementia," "Lewy body dementia," "frontotemporal dementia," "post-traumatic dementia," "Parkinson's disease dementia," "alpha-synuclein," "Huntington's disease," "normal pressure hydrocephalus," "Creutzfeldt–Jakob disease," "Down syndrome," and related terms. Inclusion criteria encompassed studies published in English, human subjects, and those focusing on epidemiology, etiology, clinical features, diagnostic criteria, biomarkers, treatment options, and research advancements in the field of dementia. Exclusion criteria included studies not meeting the inclusion criteria, duplicates, conference abstracts, and non-peer-reviewed sources. Data extraction and synthesis were conducted to summarize key findings, identify gaps in knowledge, and formulate recommendations for future research and clinical practice in the realm of dementia. Quality assessment tools such as the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) were utilized to ensure the rigor and transparency of the systematic review process. Ethical considerations were adhered to regarding data integrity, confidentiality, and citation of

sources in accordance with academic standards and ethical guidelines.

Results and Discussion

The systematic review yielded a comprehensive synthesis of literature pertaining to the diverse spectrum of dementia, encompassing Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, post-traumatic dementia, Parkinson's disease-related dementia, alpha-synuclein-associated dementia, Huntington's disease, normal pressure hydrocephalus, Creutzfeldt–Jakob disease, and dementia in Down syndrome. Key findings included the prevalence and incidence rates of each dementia subtype, their respective clinical features, underlying pathophysiology, diagnostic criteria, biomarker profiles, treatment modalities, and research advancements. The prevalence of Alzheimer's disease was consistent with previous estimates, accounting for 50% to 70% of dementia cases, followed by vascular dementia at approximately 25% and Lewy body dementia at 15%. Frontotemporal dementia, while less common, presented unique challenges due to its behavioral and language variants, as well as genetic factors influencing disease progression. Post-traumatic dementia highlighted the importance of recognizing cognitive impairments following traumatic brain injury and implementing appropriate management strategies [14].

Parkinson's disease-related dementia and alpha-synuclein-associated dementia showcased the complex interplay between motor symptoms, cognitive decline, and alpha-synuclein pathology, necessitating integrated approaches for diagnosis and treatment. Rare forms of dementia, including Huntington's disease, normal pressure hydrocephalus, Creutzfeldt–Jakob disease, and dementia in Down syndrome, underscored the need for tailored diagnostic evaluations, genetic counseling, and supportive care interventions. The discussion delved into the implications of these findings for clinical practice, research, and public health policy. Challenges in differential diagnosis, early detection, access to specialized care, and caregiver support were identified, calling for multidisciplinary collaborations and innovative solutions. Advances in genetic testing, neuroimaging techniques, biomarker discovery, and disease-modifying therapies were highlighted as promising avenues for improving diagnostic accuracy, prognostic assessment, and personalized treatment strategies in dementia care.

Furthermore, the study emphasized the importance of ongoing research efforts, knowledge dissemination, education, and advocacy to address the growing burden of dementia globally. Future research directions should prioritize longitudinal studies, translational research, innovative technologies, and community-based interventions aimed at enhancing early intervention, disease management, and quality of life outcomes for individuals living with dementia and their caregivers.

Conclusion

In conclusion, this study offers a comprehensive overview of the diverse landscape of dementia, including Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, and other less common subtypes. The findings underscore the significant burden of dementia on individuals, families, and healthcare systems globally. Diagnostic challenges, treatment modalities, and research advancements were discussed, highlighting the need for early detection, personalized interventions, and multidisciplinary collaboration in dementia care. Moving forward, continued research efforts, innovative strategies, and holistic approaches are essential to address the growing challenges posed by dementia and improve outcomes for affected individuals and their caregivers.

Acknowledgment

None

Conflict of Interest

None

References

1. Alves G, Wentzel-Larsen T, Larsen JP (2004) Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 63: 1908-1911
2. Brodie MJ, Elder AT, Kwan P (2009) Epilepsy in later life. Lancet neurology11:1019-1030.
3. Cascino GD (1994) Epilepsy: contemporary perspectives on evaluation and treatment. Mayo Clinic Proc 69: 1199-1211.
4. Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, et al. (2011) Ten-Year outcome of subthalamic stimulation in Parkinson disease: a Blinded evaluation. Arch Neurol68: 1550-1556.
5. Chang BS, Lowenstein DH (2003) Epilepsy. N Engl J Med 349: 1257-1266.
6. Cif L, Biolsi B, Gavarini S, Saux A, Robles SG, et al. (2007) Antero-ventral internal pallidum stimulation improves behavioral disorders in Lesch-Nyhan disease. Mov Disord 22: 2126-2129.
7. De Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-35.
8. Debru A (2006) The power of torpedo fish as a pathological model to the understanding of nervous transmission in Antiquity. C R Biol 329: 298-302.
9. Fisher R, van Emde Boas W, Blume W, Elger C, Genton P, et al. (2005) Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46: 470-472.
10. Friedman JH, Brown RG, Comella C, Garber CE, Krupp LB, et al. (2007) Fatigue in Parkinson's disease: a review. Mov Disord 22: 297-308.
11. Friedman JH, Friedman H (2001) Fatigue in Parkinson's disease: a nine-year follow up. Mov Disord 16: 1120-1122.
12. Friedman J, Friedman H (1993) Fatigue in Parkinson's disease. Neurology 43:2016-2018.
13. Fritsch G, Hitzig E (1992) Electric excitability of the cerebrum. Epilepsy Behav 15-27.
14. Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, et al. (2010) Deep Brain Stimulation for Intractable Obsessive Compulsive Disorder: Pilot Study Using a Blinded, Staggered-Onset Design. Biol Psychiatry 67: 535-542.